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INTRODUCTION
Rhabdomyosarcoma (RMS) is a family of pediatric soft tissue tumors associated with the skeletal muscle lineage (1) . As the most common soft tissue sarcoma of children and adolescents (2), RMS comprises two major subtypes: fusion-positive and fusion-negative. Although most fusion-positive RMS tumors are characterized by the PAX3-FOXO1 gene fusion (3), a smaller subset of cases has a PAX7-FOXO1 fusion (4). Fusion-negative RMS tumors do not harbor recurrent gene fusions. These molecular differences correspond to clinically distinct phenotypes, as fusion-positive (~80% of alveolar) RMS is more aggressive and has an unfavorable prognosis compared to fusion-negative (>95% of embryonal) RMS (5) (6) (7) . This clinical difference is attributable to the propensity of fusion-positive RMS for early dissemination, poor response to therapy, and frequent relapse (6) . The estimated 5-year overall survival rate for fusion-positive RMS cases is ~25% compared to ~75% for fusion-negative tumors (8) , which underscores the need for more effective therapeutic strategies in fusion-positive RMS.
A particularly aggressive subset of fusion-positive RMS tumors was found to harbor amplification of chromosomal region 12q13-q14 (9, 10) . This region, which contains the cyclindependent kinase 4 (CDK4) locus, was amplified in ~25% of PAX3-FOXO1-positive tumors and ~4% of PAX7-FOXO1-positive tumors (9) . CDK4 amplification or overexpression occurs in numerous adult malignancies, including breast carcinoma, lymphoma, melanoma, and sarcoma (11) (12) (13) , most notably in >95% of well-differentiated and dedifferentiated liposarcomas (14) (15) (16) .
In addition to RMS, CDK4 is also amplified or overexpressed in other pediatric tumor types, such as neuroblastoma (17, 18) . Author Manuscript Published OnlineFirst on March 25, 2015 ; DOI: 10.1158/1078-0432.CCR- As one of three interphase CDKs that promote cell cycle progression from G 1 to S phase, CDK4 is a well-established proto-oncogene (11, 19) . Upon mitogenic stimulation, CDK4 and CDK6 form active complexes with D-type cyclins and initiate inactivation of retinoblastoma (RB) and related proteins via direct phosphorylation (20) . Phosphorylation of RB proteins results in their dissociation from transcriptional repressor complexes, thereby activating E2F-dependent expression of genes that promote the G 1 -S-phase transition of the cell cycle and ultimately drive proliferation (19, 20) . The tumor suppressor p16 INK4A negatively regulates this signaling cascade by inhibiting assembly and activation of cyclin D-CDK4/6 complexes (12, 13) .
Recent development of a new generation of highly selective small molecule inhibitors targeting CDK4/6 has renewed attention to CDK4/6 inhibition as a potential therapeutic strategy in various tumor types. Three orally bioavailable, selective CDK4/6 inhibitors, including PD0332991, LY2835219, and LEE011, have entered clinical trials, with PD0332991 being the most advanced in development (21) . LEE011 is currently undergoing evaluation as a single agent or in combination therapy in Phase I/II studies in several tumor settings, such as breast cancer (NCT01872260, NCT02088684, NCT01919229), pediatric malignancies, including malignant rhabdoid tumors and neuroblastoma (NCT01747876), and tumors with CDK4/6 pathway activation (NCT02187783). In accordance with previous studies positively associating CDK4 amplification with vulnerability to CDK4/6 inhibition (17, 22) , one criterion for inclusion in the latter trial is amplification of CDK4. This Phase II study underscores the prevailing dogma of CDK4/6-targeted therapies.
Here, we demonstrate that CDK4 is necessary for proliferation and tumor progression but overexpression is not sufficient to increase RB-E2F signaling, cell cycle progression, proliferation, or transformation in fusion-positive RMS. Additionally, we report the first 6 preclinical evaluation of LEE011 in the setting of fusion-positive RMS and propose a novel model of tumor sensitivity to CDK4/6 inhibition in which CDK4 amplification and resultant overexpression confer reduced rather than enhanced susceptibility to LEE011 and PD0332991.
Although responses varied, all fusion-positive RMS cell lines evaluated demonstrated sensitivity to CDK4/6 inhibition. Thus, our data support the clinical development of CDK4/6-targeted therapies in this refractory pediatric tumor and suggest that low CDK4-expressing fusionpositive RMS tumors may be especially vulnerable to CDK4/6 inhibition.
MATERIALS & METHODS

Cell culture
Cell lines and their source are as follows: Rh30-American Type Culture Collection; Rh28-Dr.
Beverly Emanuel; Rh5, IMR5, and SKNAS-Dr. Javed Khan; CW9019-Dr. Jaclyn Biegel;
Rh41 and SMS-CTR-Dr. Corinne Linardic; RD-Dr. Lee Helman; Rh18-Dr. Maria Tsokos; Rh6-Dr. Peter Houghton; OsACL-Dr. David Shapiro; primary human myoblasts-Dr. Grace
Pavlath. Verification of cell line identity was performed in July 2014 by short tandem repeat genotyping analysis using the AmpFLSTR profiler plus PCR amplification kit (Applied Biosystems). Genotyping results are consistent with publicly available data and confirm that all cell lines are clonally independent. RMS and neuroblastoma cells were cultured using DMEM or RPMI-1640 media (Life Technologies) supplemented with 10% FBS (Atlanta Biologicals) and antibiotic-antimycotic (Life Technologies) at 37 °C in 5% CO 2 . Primary human myoblasts were cultured as previously described (23 
Inducible RNAi expression
For isopropyl β-D-1-thiogalactopyranoside (IPTG)-inducible RNAi, the pLKO-puro-IPTG3xLacO vector (Sigma) expressing non-targeting (NT) control shRNA (Sigma) or 3 different shRNAs targeting CDK4 (TRCN0000000362, TRCN0000000363, and TRCN0000010520; Thermo Scientific) were used. Cells were treated with IPTG (Sigma) for 48 h to induce CDK4 knockdown.
Inducible cDNA expression
The pINDUCER10 lentiviral vector (24) was provided by Dr. Ji Luo. Human CDK4 or CDK6
were PCR amplified from the CDK4-MigR1 retroviral vector (25) or the CDK6-pCMV6-XL6 vector (Origene), respectively, subcloned into the AgeI and MluI sites of pINDUCER10, and sequence verified. Cells were incubated with doxycycline (Sigma) for 24 h to induce CDK4 or CDK6 expression.
Western blot analyses
Cells were lysed with RIPA buffer containing Halt protease and phosphatase inhibitor cocktail (Thermo Scientific). Proteins were resolved on pre-cast gels using Criterion (Bio-Rad) or Bolt Mini Gel (Life Technologies) systems. Chemiluminescence was measured using a ChemiDoc XRS+ system (Bio-Rad), and images were analyzed with Image Lab software (Bio-Rad).
Additional details and antibodies are provided in Supplemental methods. Dynabeads Protein G (Life Technologies) coupled to non-immune mouse serum (Santa Cruz Biotechnology, sc-2025) or anti-CDK4 antibody (Santa Cruz Biotechnology, sc-23896) was incubated with whole cell lysates (100 μg) overnight at 4 °C. After three washes, proteins were eluted in BOLT LDS sample buffer (Life Technologies) and analyzed by Western blot.
Co-Immunoprecipitation (Co-IP) analysis
Proliferation and focus formation assays
For proliferation assays, 50,000 cells per well were seeded in a 6-well plate, and cell number was counted using a Cellometer Vision cytometer (Nexcelom Bioscience) on the days indicated by the trypan blue exclusion method. To measure cell viability using CellTiter-Glo (Promega), 5000 cells/well were seeded in 96-well plates. For focus formation assays, 1000 RMS cells were seeded in 10 cm plates in the presence of 1 million NIH 3T3 cells, and medium containing IPTG or doxycycline was replenished every 72 h. Foci were stained 2 weeks later with Giemsa solution (Sigma) and counted using ImageJ software (National Institutes of Health [NIH]).
Quantitative Real-Time-PCR (qPCR)
Total RNA was isolated from cells using the RNeasy kit (Qiagen) and was reverse transcribed with the high-capacity cDNA reverse transcription kit (Applied Biosystems). qPCR was performed on a ViiA7 Real-Time PCR system with ViiA7 software (Applied Biosystems).
Taqman gene expression assays (Life Technologies) were used to amplify CDK4 (Hs01565683), CDC25A (Hs00947994), CCNE2 (Hs00180319), and GAPDH (Hs02758991). For cell culture studies, PD0332991 (Sigma) and LEE011 (MedChem Express) were reconstituted in water and DMSO, respectively, according to manufacturer's instructions. Cells were treated with CDK4/6 inhibitors for 72 h. IC 50 values were calculated using nonlinear regression on normalized fluorescence measurements and log-transformed inhibitor concentrations (GraphPad Prism). For in vivo studies, LEE011 salt (MedChem Express) was dissolved in 0.5% methylcellulose (Sigma).
Cell cycle analysis
Cells were labeled with bromodeoxyuridine (BrdU), fixed, permeabilized, and stained using an anti-BrdU fluorescent antibody and 7-AAD according to the APC BrdU flow kit (BD Pharmingen) instructions. Flow cytometry was performed on a Becton Dickinson FACS Calibur using Cell Quest software (BD). Data were analyzed using FlowJo software (Tree Star).
Tissue microarray (TMA) of RMS patient tumors
We obtained a RMS TMA from the Children's Oncology Group (COG) BioPathology Center.
The TMA was comprised of tumor cores from control tissues and 70 diagnostic patient tumors, of which 58 tissues (n=29 fusion-positive tumors; n=29 fusion-negative cases) were evaluable. 
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Immunohistochemistry (IHC)
IHC was performed for CDK4 with a mouse monoclonal antibody from Life Technologies (clone DCS-31) at a dilution of 1:1000. Slides were deparaffinized in xylene, rehydrated in graded alcohols, and subjected to antigen retrieval in citrate buffer (pH 9) in a pressure cooker for 20 min. After incubation with primary antibody for 60 min. at room temperature, the antigenantibody complex was detected with Dako Envision+ detection system and 3,3'-diaminobenzidine. Concurrent positive and negative controls were stained. Tissues were imaged at 100X total magnification. Immunoreactivity was scored on a scale of 0-4 for 1) staining intensity (negative, low, medium, high, very high) and 2) percentage of positive cells (0, <25%, 25-50%, >50%, ~100%). Scores of the two parameters were multiplied for a staining score of 0-
16.
Fluorescence in situ hybridization (FISH)
FISH assays were performed on 5 micron formalin-fixed paraffin-embedded tumor sections using a laboratory standardized protocol with slight modifications (27) . Slides were analyzed on the BioView Duet-3 fluorescent scanning station using 63X-oil objective and 
Microarray analysis of tumor samples with and without 12q13-q14 amplification
Twelve tumors (n=6 with 12q13-q14 amplification; n=6 without 12q13-q14 amplification) were selected from 57 cases reported in a previous study (9) . Criteria for selection included PAX3-FOXO1 expression, prior analysis by copy number arrays (9) , and availability of RNA.
Oligonucleotide microarray expression analysis was performed on the 12 selected cases using the Affymetrix GeneChip Human Gene 1.0 ST Array at the University of Pennsylvania Microarray Facility. We defined a gene as overexpressed in a sample if its expression level was >1 standard deviation (SD) from the mean expression level of that gene across all samples. More stringent analysis was also performed by defining overexpression as >2 SD from the mean. The total number of overexpressed genes in each sample was used as a relative measure of E2F pathway activation. Additional details are described in Supplemental methods. 
RESULTS
CDK4 is overexpressed in fusion-positive RMS harboring amplification of chromosomal region 12q13-q14
We investigated whether CDK4, a well-characterized proto-oncogene, drives the oncogenic phenotype in fusion-positive RMS with 12q13-q14 amplification. To test this, we first evaluated CDK4 protein expression in RMS cell lines. As predicted, CDK4 levels were highest in Rh30 cells, which harbor the 12q13-q14 amplicon, compared to fusion-positive and fusionnegative cells lacking 12q13-q14 amplification ( Fig. 1A and 1B ). Low-level amplification of the 12q13-q14 region was also evident in Rh18 cells (Fig. 1B) , which expressed elevated CDK4 levels relative to non-amplified, fusion-negative cells but decreased CDK4 compared to Rh30 and the CDK4-amplified (29) osteosarcoma cell line OsACL ( Fig. 1D and 1F ). Taken together, these data demonstrate that CDK4 is overexpressed in fusion-positive RMS cell lines and tumors harboring the 12q13-q14 amplicon.
Depletion of CDK4 inhibits fusion-positive RMS cell proliferation and transformation via RB-E2F-mediated G 1 -phase cell cycle arrest
We next investigated whether high-level expression of the CDK4 oncoprotein is required for proliferation and transformation in fusion-positive RMS with amplification of 12q13-q14. To test this, we generated Rh30 cells stably expressing IPTG-inducible NT control shRNA or three different IPTG-inducible shRNAs targeting CDK4 (shCDK4). CDK4-targeting shRNAs #2 and #3 were employed, as they yielded the greatest reduction in CDK4 protein (Supplemental Fig. 1B and 1C) . Levels of CDK4 knockdown achieved by 75 μM IPTG were generally comparable to endogenous CDK4 protein expression in nonamplified RMS cell lines (Supplemental Fig. 1A) . Consistent with canonical cyclin D1/CDK4-RB signaling (20, 30) and previous studies of CDK4 knockdown in other tumor categories (22) , phosphorylation of RB at Ser795−a CDK4-specific phosphorylation residue (31)−was diminished in Rh30 cells depleted of CDK4 ( Fig. 2A) . CDK4 knockdown also resulted in reduced total RB, though RB hypophosphorylation was the predominant effect, as evidenced by decreased phospho-RB to RB ratios compared to NT control or vehicle-treated shCDK4-expressing cells (Fig. 2A) . Reduction in both RB phosphorylation and total RB was observed upon CDK4 knockdown in previous studies (17, 22) , suggesting that CDK4 may regulate RB via phosphorylation as well as stability/degradation mechanisms (32) . expression by qPCR in Rh30 cells with CDK4 knockdown. Consistent with microarray data, mRNA levels of CDC25A and CCNE2 were reduced in cells depleted of CDK4 compared to vehicle-treated cells (Fig. 2C) . These results confirm the role of CDK4 as an upstream component in the RB-E2F signaling axis (20) and collectively indicate that, in CDK4-amplified Rh30 cells, high CDK4 expression is required for E2F target gene expression.
To investigate the functional role of CDK4 in the 12q13-q14 amplicon, we evaluated the consequences of CDK4 knockdown on cell proliferation and oncogenic transformation in Rh30 cells. In cells depleted of CDK4, we observed decreased proliferation rates relative to NT control-expressing cells (Fig. 2D) . Suppression of proliferation correlated with the degree of CDK4 reduction, as CDK4 knockdown induced by 75 μM IPTG attenuated proliferation more dramatically than that induced by 10 μM IPTG. Similarly, focus formation was reduced upon CDK4 knockdown in an IPTG dose-dependent manner, suggesting that CDK4 is necessary for the transformed phenotype of 12q13-q14 amplified, fusion-positive RMS (Fig. 2E) .
Given that CDK4 promotes G 1 to S-phase progression in the cell cycle (11), we hypothesized that the diminished proliferative and transformative capacity of cells depleted of CDK4 is mediated by G 1 -phase cell cycle arrest. Indeed, flow cytometry analyses revealed accumulation of cells in G 1 upon CDK4 knockdown (Fig. 2F) . The percentage of cells in the sub-G 1 phase was unchanged by CDK4 depletion, suggesting that apoptosis is not a major mechanism underlying repression of proliferation and transformation in 12q13-q14 amplified, fusion-positive RMS. Moreover, we observed no morphological differences (data not shown), and levels of myogenin and myosin heavy chain−markers of early and late myogenic differentiation, respectively−remained constant in cells depleted of CDK4 compared to control cells, indicating that reduced proliferation and focus formation are not attributable to cells (Supplemental Fig. 1D ). Collectively, these data demonstrate that CDK4 is necessary for RB-E2F-mediated cell cycle progression from G 1 to S phase, thereby promoting proliferation and transformation in fusion-positive RMS cells with 12q13-q14 amplification.
Additionally, we examined the functional consequences of IPTG-inducible CDK4 depletion in fusion-positive RMS cells that lack 12q13-q14 amplification (Fig. 1B) . IPTG treatment of Rh41 cells stably expressing shCDK4s #2 and #3 induced CDK4 depletion in a dose-dependent manner at the protein (Supplemental Fig. 2A ) and mRNA levels (Supplemental Fig. 2B ). As endogenous CDK4 expression is lower in Rh41 cells compared to Rh30 cells (Fig.   1A ), CDK4 knockdown in this non-amplified cell line diminished CDK4 protein to nearly undetectable levels (Supplemental Fig. 2A) . Knockdown of CDK4 inhibited proliferation (Supplemental Fig. 2C ) and focus formation (Supplemental Fig. 2D ) in Rh41 cells as robustly as that in Rh30 cells (Fig. 2D and 2E ), suggesting that CDK4 is necessary for proliferation and transformation in fusion-positive RMS independent of 12q13-q14 amplification status.
CDK4 knockdown suppresses tumor growth of fusion-positive RMS harboring 12q13-q14 amplification in vivo
We next investigated whether depletion of CDK4 could repress 12q13-q14-amplified, fusion-positive RMS tumor growth in vivo. Intramuscular xenograft tumors were derived from Rh30 cells stably expressing IPTG-inducible NT control shRNA or shCDK4 #3, and mice received either no IPTG or 10 mM IPTG in the drinking water after formation of a palpable tumor. In mice with shCDK4 that received IPTG, tumor progression was significantly retarded compared to NT control or vehicle-treated shCDK4 xenograft tumors (Fig. 3A) . CDK4 knockdown was apparent at the protein (Fig. 3B ) and mRNA levels (Fig. 3C ) in xenograft tumors induced to express shCDK4. Reduced CDK4 mRNA levels were evident in vehicletreated shCDK4 tumors relative to NT control tumors (Fig. 3C) , though tumor growth rates in these cohorts were comparable (Fig. 3A) . Thus, leaky expression of CDK4-targeting shRNA appears to be inconsequential, as it failed to manifest phenotypically in our xenograft models.
Consistent with previous reports, we observed no deleterious effects of IPTG (41) . These data indicate that CDK4 is required for optimal tumor progression in 12q13-q14-amplified, fusionpositive RMS.
CDK4 overexpression fails to increase RB-E2F signaling, cell cycle progression, proliferation, or transformation in fusion-positive RMS lacking 12q13-q14 amplification
Given that CDK4 knockdown resulted in diminished RB-E2F signaling ( Fig. 2A, 2B , and 2C), we investigated whether E2F-regulated transcription would increase in response to CDK4 overexpression. To test this, we generated Rh41 cells stably expressing doxycyclineinducible empty vector control or CDK4. CDK4 protein levels in CDK4-transduced cells treated with 50 ng/ml doxycycline were comparable to endogenous CDK4 protein expression in 12q13-q14-amplified Rh30 cells, and 1 μg/ml doxycycline resulted in maximal CDK4 expression (Fig.   4A ). CDC25A and CCNE2 mRNA levels were unaffected by CDK4 overexpression induced by either doxycycline concentration (Fig. 4B) , suggesting that CDK4 overexpression is not sufficient to enhance E2F-responsive gene expression in Rh41 cells. harboring 12q13-q14 amplification versus those lacking amplification, no significant difference in expression of RB-E2F pathway genes was observed between cohorts (data not shown). As an alternative strategy, we analyzed expression of genes containing the consensus E2F-binding site (33) in these 12q13-q14-amplified and non-amplified fusion-positive RMS tumors but did not detect any significant difference between groups in the number of overexpressed E2F-responsive genes per sample ( Fig. 4C; p=0.32 ).
Next, we investigated the functional consequences of overexpressing CDK4 in Rh41 cells. Consistent with unaltered expression of downstream RB targets, CDK4 overexpression failed to significantly enhance cell cycle progression (Fig. 4D) , proliferation (Fig. 4E ), or focus formation (Fig. 4F ). Co-IP experiments demonstrate that levels of CDK4-associated cyclin D1 remain constant as CDK4 expression increases (Fig. 4G) , suggesting that CDK4 overexpression has no significant functional effects because cyclin D1 levels are limiting. Importantly, overexpression of CDK4 in the absence of cyclin D1 overexpression recapitulates the CDK4 and cyclin D1 expression profiles identified in our analyses of fusion-positive RMS tumors with and without 12q13-q14 amplification. Taken together, these data indicate that CDK4 overexpression is not sufficient to increase E2F-regulated transcription, G 1 -S-phase cell cycle transition, proliferation, or transformation in fusion-positive RMS.
Fusion-positive RMS cell lines are sensitive to pharmacologic inhibition of CDK4/6
Given the marked attenuation of proliferation and transformation observed in 12q13-q14- (Fig. 5A ). Sensitivity to LEE011 suggested an inverse correlation with CDK4 protein expression, though this association is based on a small number of cell lines (Fig. 1A) . Relative sensitivities of fusion-positive cell lines to the CDK4/6 inhibitor PD0332991 also corresponded to CDK4 protein levels and were consistent with the range of sensitivities observed upon LEE011 treatment (Supplemental Fig. 3A) . Although we focused evaluation of CDK4/6 inhibition on fusion-positive RMS cell lines, preliminary studies of fusion-negative RMS cell lines generally revealed attenuated sensitivity to LEE011 compared to fusion-positive cells (Supplemental Fig. 3B ). In accordance with their relative insensitivity to CDK4/6 inhibition, fusion-negative RMS cell lines displayed lower levels of RB than fusionpositive cell lines (Fig. 1A) .
If LEE011 specifically inhibits CDK4/6, then we predicted that LEE011 treatment should phenocopy CDK4 depletion. Indeed, RB phosphorylation and FOXM1, another CDK4 target (42) , were reduced in cells treated with LEE011 (Fig. 5B) . Moreover, mRNA levels of E2F targets, including CDC25A and CCNE2, were diminished in all fusion-positive RMS cell lines evaluated, though decreases in their expression did not strictly correlate with relative sensitivities to LEE011 (Fig. 5C ). As observed upon CDK4 knockdown (Fig. 2F) and consistent with previous studies of CDK4/6 inhibition (17, 22, 43) , treatment with LEE011 resulted in G 1 -phase cell cycle arrest (Fig. 5D) Based on our findings that low CDK4-expressing Rh28 cells were most sensitive to LEE011 while high CDK4-expressing Rh30 cells were least sensitive, we investigated whether overexpression of CDK4 attenuates sensitivity to CDK4/6 inhibition in fusion-positive RMS. To test this in an isogenic system, we treated Rh41 cells stably expressing doxycycline-inducible empty vector control or CDK4 with 10 μM LEE011 and a range of doxycycline concentrations (50-1000 ng/ml). Viability of control cells and CDK4-transduced cells not receiving doxycycline was reduced by ~30% upon LEE011 treatment (Fig. 5E ). In contrast, viability of CDK4-transduced cells treated with 50-1000 ng/ml doxycycline was not significantly decreased by LEE011 relative to vehicle-treated cells (Fig. 5E) . Similar results were found using PD0332991 (Supplemental Fig. 3C ). Consistent with enhanced viability (Fig. 5E and Supplemental Fig. 3C ), rescue of phospho-RB and total RB was evident in LEE011-treated cells overexpressing CDK4 (Fig. 5F ).
Given that LEE011 is a dual CDK4/6 inhibitor, we reasoned that CDK6 expression might also influence responsiveness to LEE011 in fusion-positive RMS. As Rh41 cells endogenously express the highest levels of CDK6 (Fig. 1A) , we employed another isogenic system in which Rh28 cells stably expressing doxycycline-inducible control, CDK4, or CDK6 constructs were treated with 1 μM LEE011 and 50-1000 ng/ml doxycycline (Fig. 5G) . LEE011 decreased viability of control cells and non-doxycycline-treated CDK4-or CDK6-transduced cells by ~50%, and viability of CDK4-and CDK6-transduced cells treated with 100-1000 ng/ml doxycycline was rescued (Fig. 5H ). These data demonstrate that fusion-positive RMS cell lines 
CDK4/6 inhibition abrogates fusion-positive RMS tumor growth in vivo
We interrogated whether the relative in vitro sensitivities of fusion-positive RMS cells to CDK4/6 inhibition could be recapitulated in xenograft tumors derived from Rh30 and Rh28 cells, which represented the extremes of response measured in cell culture. As observed in vitro, LEE011 reduced RB phosphorylation (Fig. 6A) . Consistent with CDK4 knockdown experiments ( Fig. 2A) and prior investigation of LEE011 in vivo (22) , total RB levels also decreased in response to LEE011 (Fig. 6A) , further supporting CDK4-mediated regulation of RB at the levels of phosphorylation and stability/degradation (32) . LEE011 significantly delayed tumor progression in both models, but activity was more robust in Rh28-derived (Fig. 6B ) compared to Rh30-derived (Fig. 6C ) xenograft tumors. Similar to previous studies (17, 22) , we dosed mice with 200 mg/kg daily; however, Phase I studies of LEE011 defined the recommended Phase II dose at 600 mg/day (44) . Despite the high dosage administered relative to that achievable in patients, LEE011 was well tolerated, as no significant weight loss or adverse events were observed in mice (data not shown). These data demonstrate in vivo antitumor activity of LEE011 as a single agent in fusion-positive RMS and are consistent with the proposed inverse relationship between CDK4 expression and CDK4/6 inhibitor sensitivity in this pediatric tumor setting. In the context of fusion-positive RMS, we introduce a novel model of CDK4-amplified tumor sensitivity in which CDK4 amplification and resultant overexpression reduce rather than enhance sensitivity to CDK4/6 inhibition. Analysis of the antiproliferative effects of pharmacologic CDK4/6 inhibitors provided initial evidence of this notion, as lowest CDK4-expressing Rh28 cells showed the highest sensitivity to both LEE011 and PD0332991, while correlated with the antiproliferative effects of LEE011 in fusion-positive RMS cell lines.
DISCUSSION
Similarly, previous studies of PD0332991 in RMS (43) and LEE011 in non-CDK4-amplified neuroblastoma (17) found no strict association between CDK4 or CDK6 levels and response to CDK4/6 inhibition. It is clear, however, that sensitivity to CDK4/6 inhibitors depends on the presence of functional RB. Indeed, RB status has been proposed as a selective biomarker of CDK4/6 inhibitor utility (22) , though additional work is needed to refine such predictive biomarkers of response. Investigations in ovarian cancer revealed that high RB and low p16 levels conferred greatest sensitivity to PD0332991 (48). Interestingly, in our studies, Rh28 cells, which exemplified this model of high RB and low p16 expression, were the most responsive to LEE011 and PD0332991, warranting further examination of this expression signature as a potentially useful biomarker in predicting response to CDK4/6 inhibition in the context of fusion-positive RMS.
Our preliminary evaluation of fusion-negative RMS cell lines showed lower RB protein levels and relative resistance to LEE011 compared to fusion-positive cell lines. In one study of RMS tumors, RB protein expression was generally comparable between fusion-negative and fusion-positive cases (49); however, protein expression of cyclin E and E2F1-both E2F targets 
